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Abstract
Background: The effects of changes in cooling temperature on biomarker levels in exhaled breath
condensate have been little investigated. The aim of the study was to test the effect of condensation
temperature on the parameters of exhaled breath condensate and the levels of selected
biomarkers.
Methods: Exhaled breath condensate was collected from 24 healthy subjects at temperatures of
-10, -5, 0 and +5 C degrees. Selected parameters (condensed volume and conductivity) and
biomarkers (hydrogen peroxide, malondialdehyde) were measured.
Results:  There was a progressive increase in hydrogen peroxide and malondialdehyde
concentrations, and condensate conductivity as the cooling temperature increased; total
condensate volume increased as the cooling temperature decreased.
Conclusion:  The cooling temperature of exhaled breath condensate collection influenced
selected biomarkers and potential normalizing factors (particularly conductivity) in different ways
ex vivo. The temperature of exhaled breath condensate collection should be controlled and
reported.
Background
Exhaled breath condensate (EBC) is a biological fluid that
mainly consists of water, but also contains small droplets
of airway lining fluid. Much of the interest of EBC lies in
the fact that its collection is totally non-invasive and does
not lead to any discomfort or risk [1]. It has been used to
assess inflammatory airway diseases such as asthma [2],
chronic obstructive pulmonary disease [3], lung cancer
[4], interstitial lung disease [5] and acute respiratory dis-
tress syndrome [6], and has recently also been extended to
the biological monitoring of workers exposed to cobalt
and tungsten [7].
EBC contains both volatile and non-volatile substances.
Volatile or semi-volatile substances have appreciable
vapour pressure at body temperature, and can therefore be
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breathed out as gases; furthermore, volatile substances in
gaseous phase can be dissolved in condensed water during
EBC collection depending on their physico-chemical
properties [8]. Non-volatile substances, such as salts and
proteins, are mainly expired in small droplets, and further
diluted with exhaled water vapours [8,9]. It is thought that
the droplets are formed as a result of random convective
processes, and may not be directly related to water vapour
production.
This has raised the question of variable droplet dilution,
and given rise to some concerns regarding the interpreta-
tion of EBC biomarkers on the basis of their absolute con-
centration [9]. Some authors have suggested normalising
for ion concentrations (Na+, Cl-, K+) or urea, assuming
that they are equally concentrated in the airway lining
fluid and serum of healthy and diseased subjects [8,10],
and conductivity measurements of lyophilised EBC have
also been proposed as a normalization factor [11]. On the
other hand, the use of non-volatile parameters to normal-
ise the volatile or semi-volatile compounds in EBC could
ignore their condensation pathways as their ex vivo evapo-
ration from the airways is different from droplet conden-
sation in EBC collection systems. Ideally, a normalisation
factor should be identified among substances with the
same physical and chemical characteristics (i.e., volatility
and solubility) as the measured parameters.
Volatility is generally assessed by means of a status dia-
gram, which represents the relationship between the com-
pounds' vapour pressure and temperature [12]. In a
condensing system, the vapour pressure of volatile com-
pounds depends on condensation temperature, and so
the physical and chemical properties of exhaled com-
pounds can be weighted by changing the condensation
temperature. This may be particularly relevant in the case
of EBC, in which the condensation of each substance may
be affected by the presence of other compounds in the
same solution.
A new type of condenser has been specifically designed to
control the temperature of EBC collection, and test the
effect of different condensation temperatures on the
recovery of selected biomarkers (hydrogen peroxide,
malondialdehyde). We also measured the conductivity
after EBC lyophilisation, a parameter that reflects the
overall concentration of salts. A rigorously precise study
design controlling these aspects may represent a major
advance in our understanding of condensation mecha-
nisms, and in the validation of EBC as a suitable source of
biomarkers reflecting the pathobiology underlying lung
diseases.
Methods
Subjects
EBC was collected from 24 healthy non-smokers (table 1):
i.e. asymptomatic and non-atopic individuals with nor-
mal spirometry results who showed no bronchial hyper-
responsiveness to methacholine. The study was con-
ducted in conformity with the declaration of Helsinki and
was approved by the Ethical Committee of the University
of Parma. All of the subjects gave their informed written
consent.
Study design
The number of volunteers was exactly the same as the total
number of possible sequence combinations of 4 tempera-
tures (4! = 24). EBC was randomly collected from each
subject using a different sequence of the four tempera-
tures. The duration of the clinical part of the study was
about two weeks in order to avoid the possible influence
of climatic changes on EBC parameters. In order to assess
inter-session variability, 10 of the 24 subjects underwent
four consecutive EBC collections at the two extremes of
temperature (-10°C and +5°C).
Collecting system
TURBO-DECCS (Transportable Unit for Research on
Biomarkers Obtained from Disposable Exhaled Conden-
sate Collection Systems) is a new and commercially avail-
able device for EBC collection (ItalChill, Parma, Italy).
TURBO is a refrigerating system relying on a thermo elec-
trical module giving rise to Peltier effect, which is acti-
vated by an electronic circuit in continuous current fed
with main voltages. The cold side of the Peltier module is
connected to an aluminium support shaped to house the
test tube. A thermostat allows the collecting temperature
to be regulated with a tolerance of ±1°C. The working
Table 1: Characteristics of the study subjects. Data are expressed as mean ± SD.
Number of Subjects 24 (13 M; 11 F)
Age, Years 30 ± 4
Smokers/Ex-Smokers/Non Smokers 0/3/21
FVC, % of predicted 108.4 ± 10.4
FEV1, % of predicted 103.7 ± 11.4
FEV1/FVC, % of predicted 81.9 ± 6.3BMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
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temperature is adjustable from -10°C to room tempera-
ture or higher.
TURBO is supplied with DECCS, a disposable polyethyl-
ene device for collecting EBC that consists of a mouth-
piece equipped with a one-way valve and saliva trap,
connected to a collecting vial (50 ml) by means of a tube.
EBC collection
The subjects were asked to breath tidally through the
mouthpiece without a nose clip for 10 minutes at collect-
ing temperatures of -10°C, -5°C, 0°C and +5°C, with a 5-
min interval after every collection. The subjects collected
their EBC all in the same laboratory and no one collected
EBC at home. EBC from every subject was collected
according to different temporal combinations of the four
temperatures covering the 24 possible combinations. The
subjects were strictly instructed to maintain constant tidal
breathing during the test and to form a complete seal
around the mouthpiece; excess saliva was periodically
eliminated and the mouth was rinsed with water. Salivary
contamination was excluded by means of the colorimetric
detection of alpha-amylase (Infinity amylase reagent,
Sigma, Milan, Italy). The EBC samples were centrifuged
for 1 min at 1000 g immediately after collection so that all
of the water droplets were driven to the bottom of the
flask, and the total volumes were measured. The samples
were then stored at -80°C until analysis.
EBC analysis
Volume
The collected EBC volume was measured using a cali-
brated 200 µl pipette (Gilson International, Den Haag,
The Netherlands) with an experimental error of ±10 µl.
Conductivity
EBC was lyophilised using a Heto FD 1.0 lyophilizer
(Heto, Allerod, Denmark) and then re-suspended in ultra-
pure water (Sigma, St. Louis, MO, USA). Conductivity was
measured by means of an Istek 430c conductivity meter
(Istek, Seoul, Republic of Korea). The Limit of Detection
(LOD) of the method was about 0.1 µS/cm. Contamina-
tion of the storage vials was carefully assessed and
excluded.
Hydrogen peroxide (H2O2)
H2O2 in EBC was measured as previously described [13]
using a commercial kit (Amplex Red Hydrogen Peroxide
assay kit, Molecular Probes, Eugene, USA) with a LOD of
0.01 µM. The analysis was made within 2–3 days of EBC
collection after freezing at -80°C, in order to avoid the rel-
ative instability of H2O2 in EBC [14].
Malondialdehyde (MDA)
EBC MDA was measured by means of liquid chromatog-
raphy-mass spectrometry tandem (LC-MS/MS) as previ-
ously described [15] within two weeks of EBC collection
after storage at -80°C because of the relative high stability
of MDA [16].
Statistical analysis
Data distribution was assessed using the Shapiro-Wilk
test. Mean values ± SD were used for the normally distrib-
uted data, and geometric means [geometric SD] for the
data with a lognormal distribution. Between-group differ-
ences were calculated using one-way ANOVA for repeated
measures, followed by Tuckey's post-hoc  test using the
experimental data points or their logarithms, depending
on the distribution of the experimental values. Regres-
sions were performed using the least-squares method on
either the experimental data points or their logarithms,
using the Pearson's correlation coefficient to test good-
ness-of-fit. Intra-individual variability due to repeated
measures was assessed using the dummy variables
method for the multiple regression analysis [17]. A signif-
icance level of 0.05 was chosen for all of the statistical
tests. The data were statistically analysed using two soft-
ware programmes: SPSS 12.0 (SPSS inc., Chicago, IL,
USA) and PRISM 3.0 (Graphpad Sofware, San Diego, CA,
USA).
Results
Table 2 shows the inter-session variability in 10 of the 24
subjects at the two extreme temperatures (-10°C and
+5°C). No statistically significant differences were found
in the total volume, H2O2 level or conductivity values of
the four consecutive collections.
The measurements of the variables in the samples col-
lected at different temperatures are shown in Figures 1, 2,
3, 4, which also show their distribution parameters (mean
± SD or geometric mean [geometric SD]). There was a
clear trend toward increasing EBC sample volumes with
decreasing collection temperatures (Figure 1), which
affected both the concentration and absolute amounts of
the selected analytes to different extents.
All of the differences in volume between temperature
pairs were statistically significant, except for the compari-
son between -5°C and 0°C. At a fixed temperature, the
total volume of expired air closely correlated with the total
condensed volume (r > 0.95, data not shown).
The H2O2 concentrations measured in the EBC samples
collected at different cooling temperatures (Figure 2a)
were significantly different between -10°C and +5°C (p <
0.05). The absolute amount of H2O2 (in pmol) was calcu-
lated by multiplying its concentration by theBMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
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corresponding total condensed volume. As shown in Fig-
ure 2b, a progressive increase in the amount of EBC H2O2
was recorded as the cooling temperature decreased, with
significant differences between -10 and +5°C and
between -10 and 0°C (p < 0.01).
Figure 3a shows the differences in MDA concentration
measured in the EBC samples collected at different cool-
ing temperatures (between -10 and 0°C and between -5
and +5°C, p < 0.05; between -10 and +5°C, p < 0.01). Fig-
ure 3b shows that the absolute amount of MDA (in pmol)
decreased with increasing temperature, with some resid-
ual statistically significant differences between -10 and
0°C (p < 0.05) and between -10 and +5°C, (p < 0.01).
Table 2: Inter-session variability of the selected parameters. t1, ...., t4 represent four consecutive EBC collections from 10 healthy 
subjects. No significant differences were found using repeated measures ANOVA followed by Tuckey's post-hoc test. MDA was 
excluded from the analysis because its reliability has been previously measured [15,16]. Mean ± SD or geometric mean [geometric 
SD] are also reported.
Total Volume (µl) H2O2 (µM) Conductivity (µS/cm)
Tt 1 t2 t3 t4 t1 t2 t3 t4 t1 t2 t3 t4
-10°C 1080 ± 
270
1050 ± 
220
1120 ± 
250
1150 ± 
220
0.097 
[1.85]
0.092 
[1.95]
0.108 
[1.97]
0.112 
[1.95]
1.8 
[2.26]
2.6 
[2.76]
2.4 
[2.75]
1.5 
[2.19]
+5°C 610 ± 
200
680 ± 
230
660 ± 
250
600 ± 
250
0.135 
[1.92]
0.118 
[1.88]
0.125 
[1.91]
0.140 
[2.00]
6 [2.95] 4.8 
[2.70]
5.5 
[2.50]
6.5 
[2.33]
Variation in total EBC volume collected at different cooling  temperatures Figure 1
Variation in total EBC volume collected at different 
cooling temperatures. The horizontal grey lines indicate 
mean values. The parameters of the distributions (mean ± 
SD) at different temperatures and the significant differences 
are also reported. * = p < 0.05; ** = p < 0.01.
Concentration (a) and absolute amount (b) of EBC H2O2 at  different cooling temperatures Figure 2
Concentration (a) and absolute amount (b) of EBC 
H2O2 at different cooling temperatures. The horizontal 
grey lines indicate geometric mean (a) and mean values (b). 
The parameters of the distributions (geometric mean [geo-
metric SD] and mean ± SD for a and b respectively) at differ-
ent temperatures and the significant differences are also 
reported. * = p < 0.05; ** = p < 0.01.BMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
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There was a progressive increase in EBC conductivity val-
ues at different cooling temperatures (Figure 4a), with sig-
nificant differences between -10 and 0°C, between -5 and
+5°C (p < 0.05) and between -10 and +5°C (p < 0.01).
These differences disappeared when conductivity was
multiplied by volume (thus expressing results as µS*cm2),
as shown Figure 4b.
On the basis of the geometric standard deviation (GSD) of
the values shown in Figures 2a, 3a and 4a, conductivity
was more variable (range 2.17–3.35) than either H2O2
(range 1.81–1.96) or MDA (range 1.29–1.37)
concentrations.
Table 3 shows the parameters of regressions between
measured variables: Pearson's correlation coefficient with
its significance, and the intercept with Y axis (A) and the
slope (B). The regressions were performed using the least-
square method either on experimental data points or their
logarithms, with Pearson's correlation coefficient being
used to test the goodness-of-fit. Intra-individual variabil-
ity due to repeated measures was assessed using the
dummy variable method for multiple regression analysis.
The results indicated a weak negative correlation between
total volume and H2O2 (r = -0.29, p < 0.01) but, consider-
ing B values in table 3, the intra-individual contribution
Concentration (a) and absolute quantity (b) of EBC MDA at  different cooling temperatures Figure 3
Concentration (a) and absolute quantity (b) of EBC 
MDA at different cooling temperatures. The horizontal 
grey lines indicate geometric mean (a) and mean values (b). 
The parameters of the distributions (geometric mean [geo-
metric SD] and mean ± SD for a and b respectively) at differ-
ent temperatures and the significant differences are also 
reported. * = p < 0.05; ** = p < 0.01.
EBC conductivity (a) and EBC conductivity*EBC volume val- ues (b) at different cooling temperatures Figure 4
EBC conductivity (a) and EBC conductivity*EBC vol-
ume values (b) at different cooling temperatures. The 
horizontal grey lines indicate geometric mean values. The 
parameters of the distributions (geometric mean [geometric 
SD]) at different temperatures and the significant differences 
are also reported. * = p < 0.05; ** = p < 0.01.BMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
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was not significant. There was also a negative correlation
between total volume and MDA (r = -0.54, p < 0.01) with
a similar inter-individual and intra-individual contribu-
tion. Conductivity showed a similar, albeit weaker corre-
lation (r = -0.34, p  < 0.01). H2O2  and MDA levels
positively correlated (r = 0.53, p < 0.01). There was no sig-
nificant correlation between H2O2 and conductivity (r =
0.1,  p  = ns), but a significant, albeit weak correlation
between MDA and conductivity (r = 0.21, p < 0.05), with
a higher intra-individual contribution to variability.
Discussion
Although EBC is mostly water, it contains appreciable
concentrations of volatile and non-volatile solutes. The
presence of salts and peptides in EBC suggests a transfer of
non-volatile compounds to the air phase, probably in the
form of small droplets to allow the vapour stream to go
through convective processes. Mathematical models
based on in vitro experiments [18] have been developed in
order to understand more about the physical phenome-
non of droplet formation, and the size distribution of
exhaled droplets has been characterized [19,20]. Other
Authors have proposed complex mathematical models
designed to account for the presence of non-volatile sol-
utes in ambient air [21,22].
Various approaches have been proposed as a mean of nor-
malising biomarker concentrations in EBC [8-11], includ-
ing the use of endogenous non-volatile substances (ions,
urea) or parameters (osmolality, conductivity after
lyophilisation). One controversial assumption is that
serum and airway surface lining fluid are isotonic, but this
is not supported by available evidence [23-25]. Although
a normalisation factor may be useful for non-volatile mol-
ecules such as proteins and electrolytes, the ex vivo volatil-
ity of some currently measured biomarkers in EBC is still
unclear, and their normalization by any non-volatile
factor could actually lead to ignore their different exhala-
tion pathways and consequent focusing ability in EBC col-
lecting systems.
In this study, we assessed the ex vivo volatility of H2O2 and
MDA, which are respectively considered to be reliable
biomarkers of airway inflammation and membrane per-
oxidation [26,27]; the volatility and solubility of H2O2 are
well known in aqueous solutions [28], but little is known
about MDA. We also measured total condensed volume,
which reflects overall subject ventilation [29], and con-
ductivity after EBC lyophilisation, which reflects the con-
centration and charge of non-volatile electrolytes [11].
As expected, total condensed volume inversely related to
temperature. On a pretty constant subject expiration, the
number of condensed water molecules derived from the
aqueous vapour phase depends on condensation temper-
ature; with lower temperatures condensating a larger
number of water molecules. Assuming an EBC density of
approximately 1 g/cm3 (near to that of pure water), the
increase in the number of water molecules in the selected
range of cooling temperatures can be calculated using the
equation:
Table 3: Regressions between the measured variables. Regressions between the measured variables using the general model (second 
column) and the dummy variable method (third column). ns = not significant. Cond. = Conductivity, Vol. = Volume. r = Pearson's 
correlation coefficient; p = significance of r; A: intercept with Y-axis (±SD is also expressed); B: Slope of the regression line (±SD is also 
expressed); p (B): significance of B. The correlations refer to the concentrations of H2O2 and MDA. Ei = dummy variable. Its value is 1 
for the i-th subject, -1 for the last subject, 0 elsewhere.
H2O2 vs Vol. Log (H2O2) = A + B*Volume Log (H2O2) = A + B*Volume + ΣiCiEi
r P AB p (B) A B p (B)
-0.29 <0.01 -0.73 ± 0.08 (-2.7 ± 0.9)*10-5 <0.01 -0.88 ± 0.08 (-8.5 ± 5.2)*10-5 ns
MDA vs Vol. Log (MDA) = A + B*Volume Log (MDA) = A + B*Volume + ΣiCiEi
r P AB p (B) A B p (B)
-0.54 <0.01 1.01 ± 0.04 (-2.4 ± 0.4)*10-4 <0.01 1.00 ± 0.04 (-2.3 ± 0.4)*10-4 <0.01
Cond. vs Vol. Log (Cond.) = A + B*Volume Log (Cond.) = A + B*Volume + ΣiCiEi
r P AB p (B) A B p (B)
-0.34 <0.01 0.94 ± 0.13 (-5.2 ± 1.5)*10-4 <0.01 1.05 ± 0.13 (-6.5 ± 1.4)*10-4 <0.01
MDA vs H2O2 Log (MDA) = A + B*Log (H2O2) Log (MDA) = A + B*Log (H2O2) + ΣiCiEi
r P AB p (B) A B p (B)
0.53 <0.01 1.05 ± 0.04 0.25 ± 0.04 <0.01 1.16 ± 0.09 0.37 ± 0.10 <0.01
H2O2 vs Cond. Log (H2O2) = A + B*Log (Cond.) Log (H2O2) = A + B*Log (Cond.) + ΣiCiEi
r P AB p (B) A B p (B)
0.12 Ns Ns ns
MDA vs. Cond. Log (MDA) = A + B*Log (Cond.) Log (MDA) = A + B*Log (Cond.) + ΣiCiEi
r P AB p (B) A B p (B)
0.21 <0.05 0.78 ± 0.02 0.06 ± 0.03 <0.05 0.76 ± 0.02 0.10 ± 0.03 <0.01BMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
Page 7 of 9
(page number not for citation purposes)
% increase water = Volume (-10°C)/Volume (+5°C) =
1.72,
On the basis of the mean values calculated in Figure 1.
This ratio is significantly different from 1 (p < 0.01).
The same equation (with different means and geometric
means depending on the data distribution) was used to
calculate the absolute amount of H2O2 and MDA. As the
ratios were significantly different from 1 (1.37 for H2O2
and 1.28 for MDA, p < 0.01, Figures 2b and 3b), these
biomarkers can be considered volatile compounds ex vivo.
In both cases, the percentage of recovery is less than that
of water. Therefore, as the condensation temperature
decreased, the increase in their absolute amount was less
than that of water.
The behaviour of EBC conductivity is an important com-
parative parameter. Like H2O2 and MDA, conductivity
increased with temperature, although in this case the
absolute increase was greater and inversely related to vol-
ume (Figure 4a). Assuming that EBC conductivity is pro-
portional to mono-charged ion EBC concentration, which
should represent more than 80% of the total [11], the
product of conductivity by volume should be approxi-
mately proportional to the number of electrolyte mole-
cules and, as expected, the differences between collection
temperatures were no longer significant (Figure 4b). This
may be due to the fact that the number of expired droplets
(and therefore the absolute amount of recovered ions) is
not temperature dependent, whereas the observed
decrease in conductivity at lower temperatures should
only depend on number of condensed water molecules
with the subsequent dilution of non-volatile substances.
We calculated the percent increase in salt molecules using
the equation:
% increase salts molecules ≈ Conductivity*Volume (-
10°C)/Conductivity*Volume (+5°C) = 0.66,
on the basis of the geometric mean values shown in figure
4b. The ratio is not significantly different from 1.
On the basis of our data, H2O2 and MDA should both be
considered volatile substances ex vivo, whereas conductiv-
ity should not. The normalisation of these volatile sub-
stances by non-volatile compounds or parameters would
therefore not take into account their specific excretion
pathway. Further, the high variability of conductivity (Fig-
ure 4a) suggests that its level in EBC is not regulated by a
specific biological elimination mechanism, but depends
on a random process, that would make its use as a nor-
malisation factor hazardous. Effros et al. [9] suggested that
volatile compounds should be measured in the gas phase
of expiration rather than in EBC, but our findings show
that, although the determination of low-volatility
compounds is influenced by the condensation tempera-
ture, their determination in EBC is not nonsensical
provided that the EBC collection temperature is fixed: at
the relatively high condensation temperature of +5°C,
about 70% of the total molecules measured at -10°C were
present in solution.
The intra-session variability study (Table 2) showed that
temperature-related differences in collected marker levels
can not be attributed to intra-individual variability. MDA
reliability was not assessed as it has already been demon-
strated [15,16].
The between-variable correlations and regressions gave
further information concerning the mutual relationships
of the compounds. When regression was calculated with-
out making any distinction for repeated measures, the
contribution of temperature was mixed with other possi-
ble contributions, such as that of ventilatory volume,
which closely correlated with the total collected volume at
a fixed temperature. Isolation of the intra-individual effect
by means of the dummy variable method distinguished
the effect of temperature from the other contributions as
the ventilatory volume of the same subject was kept con-
stant at the different temperatures, and made it possible to
estimate its effect on the parameters describing the
regression.
EBC H2O2 concentrations showed a weak negative corre-
lation with EBC total volume (r = -0.29), but this was not
significant when only the intra-individual effect was
considered (Table 3). Although the temperature-induced
variations in volume did not correlate with the variations
in H2O2 concentration, the inter-individual variability in
volume due to other contributions moderately affected
H2O2 concentrations. On the contrary, EBC MDA concen-
tration negatively correlated with total EBC volume (r = -
0.54), with a similar contribution of inter-individual and
intra-individual effect (Table 3). As a result, total volume
could be a relevant parameter, particularly if the EBC
biomarker correlates with EBC volume and the effect of
condensation temperature is ruled out. When sampling
occurs at a constant temperature, any inter-individual dif-
ference in EBC volume can be ascribed to total ventilation
volume. Under these circumstances, the use of total EBC
volume as a covariate could normalise the effect of total
ventilation volume on biomarker concentrations.
H2O2 and MDA positively correlated (r = 0.53). These data
suggest that, in addition to their volatility, hydrogen per-
oxide production and lipid peroxidation could also be
related processes in vivo in healthy subjects, as already
observed in subjects affected by respiratory tract inflam-
mation [30].BMC Pulmonary Medicine 2005, 5:10 http://www.biomedcentral.com/1471-2466/5/10
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Finally, although there was no correlation between H2O2
concentration and conductivity values, thus reinforcing
the idea that non-volatile compounds and H2O2 in EBC
have different physico-chemical properties, a very weak
positive correlation was found between MDA and conduc-
tivity (r = 0.21): this suggests that a slight contribution to
the total concentration of MDA in EBC could derive from
MDA-containing droplets. In fact, the lack of correlation
between conductivity and volatile components indicates
that non-volatile ions reflect the number of airway lining
fluid droplets joining the vapour stream, a mechanism
that would complement evaporation. The latter seems to
be the main determinant of H2O2 (which is volatile) and
MDA (which is also slightly volatile) content in EBC.
Conclusion
On the basis of the present study, we suggest that:
1. the temperature of EBC collection should be controlled
and reported;
2. cooling temperatures should be chosen on the basis of
analytical needs (required EBC volumes, sensitivity of the
method, etc.);
3. water is the main variable dilution factor, and so total
condensed volume should be recorded;
4. the cooling temperature related to EBC collection may
differently influence biomarkers and normalizing factors,
which should belong to the same class as the analytes
requiring normalization (e.g., in terms of relative volatil-
ity and solubility).
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